Document Detail

Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.
MedLine Citation:
PMID:  12668365     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: This study assessed the efficacy of two fixed doses of paroxetine in the treatment of generalized anxiety disorder. METHOD: Outpatients (N=566) with generalized anxiety disorder and no other axis I disorder were eligible if they scored >/=20 on the Hamilton Rating Scale for Anxiety (with a score of 2 or higher on the anxious mood and tension items). Following a 1-week placebo run-in phase, patients were randomly assigned to 8 weeks of treatment with paroxetine, 20 or 40 mg/day, or placebo. The primary outcome measure was the change from baseline in total score on the Hamilton anxiety scale. Response was defined as a rating of "very much improved" or "much improved" on the Clinical Global Impression global improvement measure; remission was defined as a Hamilton anxiety scale score </=7. Change in functional impairment was measured with the Sheehan Disability Scale. RESULTS: At 8 weeks, reductions in total score on the Hamilton anxiety scale were significantly greater for both paroxetine groups. Response was achieved by 62% and 68% of the patients receiving 20 and 40 mg of paroxetine, respectively, compared with a 46% response rate in the placebo group. Remission was achieved by 30% and 36% of patients in the 20- and 40-mg paroxetine groups, respectively, compared with 20% given placebo. For all three domains of the Sheehan Disability Scale, significantly greater improvement was seen with paroxetine than placebo. Both doses of paroxetine were well tolerated. CONCLUSIONS: This study demonstrates that paroxetine is an efficacious and well-tolerated treatment for generalized anxiety disorder.
Karl Rickels; Rocco Zaninelli; James McCafferty; Kevin Bellew; Malini Iyengar; David Sheehan
Related Documents :
16582045 - A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric out...
15367045 - A double-blind comparison of escitalopram and venlafaxine extended release in the treat...
17943025 - Relationship between g-protein beta-3 subunit c825t polymorphism and mirtazapine respon...
11128665 - Paroxetine versus amitriptyline for treatment of depression associated with rheumatoid ...
15610945 - Mirtazapine and venlafaxine in the management of collateral psychopathology during alco...
6678135 - Psychological characteristics of duodenal ulcer patients (a pilot report on 30 patients).
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The American journal of psychiatry     Volume:  160     ISSN:  0002-953X     ISO Abbreviation:  Am J Psychiatry     Publication Date:  2003 Apr 
Date Detail:
Created Date:  2003-04-01     Completed Date:  2003-05-20     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370512     Medline TA:  Am J Psychiatry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  749-56     Citation Subset:  AIM; IM    
Department of Psychiatry, University of Pennsylvania Medical Center, Philadelphia 19104-3309, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Ambulatory Care
Anxiety Disorders / diagnosis,  drug therapy*,  psychology
Dose-Response Relationship, Drug
Double-Blind Method
Drug Administration Schedule
Paroxetine / therapeutic use*
Psychiatric Status Rating Scales
Serotonin Uptake Inhibitors / therapeutic use*
Severity of Illness Index
Treatment Outcome
Reg. No./Substance:
0/Placebos; 0/Serotonin Uptake Inhibitors; 61869-08-7/Paroxetine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind,...
Next Document:  Psychiatric inpatient, outpatient, and medication utilization and costs among privately insured yout...